MXPA02005639A - Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico. - Google Patents

Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.

Info

Publication number
MXPA02005639A
MXPA02005639A MXPA02005639A MXPA02005639A MXPA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A
Authority
MX
Mexico
Prior art keywords
human papillomavirus
peptide
nucleic acid
immune responses
cellular immune
Prior art date
Application number
MXPA02005639A
Other languages
English (en)
Spanish (es)
Inventor
Howard M Grey
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of MXPA02005639A publication Critical patent/MXPA02005639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA02005639A 1999-12-10 2000-12-11 Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico. MXPA02005639A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17270599P 1999-12-10 1999-12-10
US09/641,528 US7026443B1 (en) 1999-12-10 2000-08-15 Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PCT/US2000/033549 WO2001041799A1 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

Publications (1)

Publication Number Publication Date
MXPA02005639A true MXPA02005639A (es) 2004-09-10

Family

ID=26868370

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005639A MXPA02005639A (es) 1999-12-10 2000-12-11 Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.

Country Status (7)

Country Link
US (4) US7026443B1 (enExample)
EP (1) EP1246644A4 (enExample)
JP (1) JP2004512814A (enExample)
AU (3) AU2258201A (enExample)
CA (1) CA2393960C (enExample)
MX (1) MXPA02005639A (enExample)
WO (1) WO2001041799A1 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
ATE536187T1 (de) 2000-10-19 2011-12-15 Epimmune Inc Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
US7842480B2 (en) * 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
ATE516045T1 (de) * 2003-01-24 2011-07-15 Univ Massachusetts Medical Identifikation von vaccinia-virus-dominanten t- zell-epitopen
US8067535B2 (en) * 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
US7981601B2 (en) * 2003-08-01 2011-07-19 Institute Of Basic Medical Sciences Method of preparing polyepitope chimeric gene vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US10941353B2 (en) 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
ES2585891T3 (es) 2004-04-28 2016-10-10 Headwaters Heavy Oil, Llc Métodos y sistemas de hidroprocesamiento en lecho en ebullición
WO2005104786A2 (en) * 2004-04-28 2005-11-10 Headwaters Heavy Oil, Llc Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CA2604909A1 (en) * 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20070218080A1 (en) * 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
ES2440974T3 (es) * 2007-05-31 2014-01-31 Genimmune N.V. Constructos poliepitópicos del VPH y uso de los mismos
US20110097332A1 (en) * 2007-08-06 2011-04-28 Martina Buck Composition and Method of Use for HCV Immunization
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
US8722851B2 (en) * 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
JP5707326B2 (ja) * 2008-09-02 2015-04-30 アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
DK2993183T3 (da) * 2010-02-16 2020-03-30 Oesterreichische Akademie Der Wss Anti-hpv e7-antistoffer
US20120045413A1 (en) * 2010-04-09 2012-02-23 Mayumi Nakagawa Human papilloma virus peptide-specific T-cell response for treatment of warts
TWI507413B (zh) * 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US8663964B2 (en) * 2011-07-20 2014-03-04 Tamir Biotechnology, Inc. Methods of treating human papillomavirus
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US8715681B2 (en) * 2012-02-02 2014-05-06 Hengsun Pharmaceutical Technology Co. Ltd. Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications
WO2014007584A1 (en) * 2012-07-05 2014-01-09 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
CN106478784B (zh) * 2013-02-22 2019-10-25 艾托金生物医药（苏州）有限公司 用于检测抗人乳头瘤病毒抗体的抗原及相关免疫检测试剂盒
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
EP2883550A1 (en) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
KR101677940B1 (ko) * 2014-07-18 2016-11-21 연세대학교 산학협력단 인유두종바이러스 e7 절단된 펩타이드의 자궁경부암 진단 및 치료 용도
KR101680567B1 (ko) 2014-07-09 2016-11-29 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US20180043008A1 (en) * 2015-02-26 2018-02-15 Bioventures, Llc Recall antigen for promoting t-helper type 1 response
CA2979493A1 (en) * 2015-03-16 2016-09-22 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
EP3307238A1 (en) 2015-06-15 2018-04-18 Tamir Biotechnology, Inc. Pharmaceuticals for treatment of viral infections of the eye
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
US11118119B2 (en) 2017-03-02 2021-09-14 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with less fouling sediment
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
GB201713163D0 (en) * 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
CA3079422A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019145792A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
CN109517033B (zh) * 2018-10-31 2021-02-05 深圳凯联健康生物科技有限公司 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用
CN111440811A (zh) * 2019-02-25 2020-07-24 武汉凯德维斯生物技术有限公司 同时靶向hpv16 l1及hpv16 e5e6e7的宫颈癌疫苗及其制备方法
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
CN111153967B (zh) * 2019-12-16 2023-04-07 温州医科大学 一种对hpv16 e5蛋白特异性结合的多肽及其应用
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research Compositions and methods for targeting hpv-infected cells
CN113984947B (zh) * 2020-07-27 2024-05-17 中国食品药品检定研究院 测定9价hpv疫苗中抗原蛋白含量的特异性肽段及方法
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
US20230105995A1 (en) * 2021-09-23 2023-04-06 Karen Anderson Multiplexed lateral flow assay for detection of hpv associated cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
IL63224A (en) 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
US4487715A (en) 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
FR2591227B1 (fr) 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5200320A (en) 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
US5180806A (en) 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5753233A (en) 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
SE9001705D0 (sv) 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
WO1992002543A1 (en) 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
CA2101065A1 (en) 1991-01-22 1992-07-23 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
EP0534615B1 (en) 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
DE69334155T2 (de) 1992-04-21 2008-02-14 Institut Pasteur Rekombinante mutanten zur induktion spezifischer immunantworten
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US20020177694A1 (en) 1996-01-23 2002-11-28 Alessandro Sette Hla binding peptides and their uses
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
ATE342730T1 (de) 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
WO1994020127A1 (en) 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US20050049197A1 (en) 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996022067A2 (en) 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
CA2211995A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5821048B1 (en) * 1995-06-07 2000-05-23 Harvard College Methods kits and compositions for diagnosing papillomavirus infection
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
DK0900380T3 (da) 1996-04-26 2003-11-03 Seed Capital Investments Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
JP2002507397A (ja) 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
EP1078092B1 (en) 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
CA2370413A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
CA2386341A1 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs and related methods
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040157273A1 (en) 2001-08-22 2004-08-12 John Sidney Subunit vaccines with a2 supermotifs

Also Published As

Publication number Publication date
CA2393960A1 (en) 2001-06-14
AU2258201A (en) 2001-06-18
US20070053922A1 (en) 2007-03-08
US20090214632A1 (en) 2009-08-27
AU2006200654B2 (en) 2009-07-30
AU2006200654A1 (en) 2006-03-23
EP1246644A1 (en) 2002-10-09
AU2006200654A2 (en) 2006-03-23
US20130017253A1 (en) 2013-01-17
US7572882B2 (en) 2009-08-11
WO2001041799A1 (en) 2001-06-14
US7026443B1 (en) 2006-04-11
JP2004512814A (ja) 2004-04-30
AU2006200654C1 (en) 2010-03-04
CA2393960C (en) 2015-06-02
AU2009225354A1 (en) 2009-11-05
EP1246644A4 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO1999010375A3 (en) Vaccine against hpv
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
IL150602A0 (en) Proteosome influenza vaccine
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
AU4358801A (en) Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
AU4322996A (en) Variants of human papilloma virus antigens
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
RU2002111554A (ru) Вакцина
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
WO2002070004A3 (en) Papillomavirus vaccines
AU5489500A (en) Isolation of a human retrovirus

Legal Events

Date Code Title Description
FG Grant or registration